Vivos Therapeutics, Inc. (VVOS) Stock Score, Valuation & Financial Research
Vivos Therapeutics, Inc. is in the Healthcare sector and Medical - Devices industry. It is reviewed using Wall Street Score's company-strength, valuation, growth and financial-health framework. The current Wall Street Score is 21/100.
Quick answer for VVOS
Vivos Therapeutics, Inc. currently has a Wall Street Score of 21/100. The stored market price is $0.18. Its financial score is 19/100. Its valuation score is 0/100. These figures are a research snapshot, not a buy or sell recommendation.
What Vivos Therapeutics, Inc. does
Vivos Therapeutics, Inc. operates as a medical technology company that develops and commercializes treatment modalities for patients with dentofacial abnormalities, obstructive sleep apnea (OSA), and snoring in adults. It offers The Vivos Method, a non-invasive, non-surgical, non-pharmaceutical, multi-disciplinary treatment modality for the treatment of dentofacial abnormalities, OSA, and snoring. The company also offers VivoScore Program, a screening and home sleep test in adults and children. It markets and sells its appliances, and related treatments and services to licensed professionals, primarily general dentists in the United States and Canada. The company was formerly known as Vivos BioTechnologies, Inc. and changed its name to Vivos Therapeutics, Inc. in March 2018. The company was founded in 2016 and is based in Littleton, Colorado.
VVOS financial snapshot
- Wall Street Score:
- 21/100
- Current price:
- $0.18
- Market capitalization:
- $2.5M
- Revenue:
- $19.6M
- Net income:
- $-25.1M
- Free cash flow:
- $-17.6M
- Cash:
- $2.1M
- Total debt:
- $12.3M
- EPS:
- -2.06
- Financial score:
- 19/100
- Valuation score:
- 0/100
- Revenue score:
- 42/100
What stands out
- Reported year-over-year revenue growth is +0.1%.
- Free cash flow is $-17.6M, showing cash burn in the current stored period.
- The balance sheet shows $2.1M of cash versus $12.3M of total debt, so leverage deserves attention.
What the numbers mean
Its current valuation score is 0/100, which Wall Street Score classifies as weak within the model's valuation framework.
The financial score is 19/100. This is a starting point for reviewing liquidity, leverage and cash-flow strength rather than a stand-alone recommendation.
A strong company and an attractive stock price are not always the same thing. Revenue, earnings, free cash flow, debt, management quality, competitive advantage and valuation should be considered together. Wall Street Score organizes these inputs into a consistent research framework so investors can identify what deserves deeper review.
Data freshness: Financial data last refreshed 2026-07-24.
How to research VVOS
Start by understanding how the company makes money. Then compare revenue and earnings trends, cash generation, debt, liquidity and valuation. Review the company's latest filings and earnings reports before acting on any score or model estimate.
Learn how to analyze a stock · Read the Wall Street Score methodology · Browse other stocks
Data may change as company filings and market prices update. Educational research only; not a buy or sell recommendation.